Beijing Tiantan Hospital, China National Clinical Research Center of Neurological Diseases, Advanced Innovation Center for Human Brain Protection, The Capital Medical University, Beijing, China.
Department of Cardiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou, China.
Adv Exp Med Biol. 2022;1377:171-187. doi: 10.1007/978-981-19-1592-5_14.
A wealth of evidence indicates that high-density lipoprotein assumes the unique antiatherosclerosis and other cardioprotective properties. Based on that, HDL-C has been considered as a promising therapy target to reduce the cardiovascular diseases. Recombinant HDL (rHDL) and apolipoprotein mimetic peptides emerge in recent years and have great potential in the future. Here we discussed the pleiotropic therapeutic effect of rHDL based on the effects of atherogenic, angiogenesis, platelet, vascular, and Alzheimer's disease. On the other hand, rHDL not only plays the key role as the major protein component of HDL, it is also used as a nanovector in antiatherosclerotic, antitumor, cardiovascular diagnosing and other therapeutic areas. Synthetic apolipoprotein mimetic peptides like apoA-I and and apoE mimetics have undergone clinical assessment, and we have also reviewed the advances of clinical trials and gave an outlook for the therapy of rHDL and mimetic peptides.
大量证据表明，高密度脂蛋白（HDL）具有独特的抗动脉粥样硬化和其他心脏保护特性。基于这一点，HDL-C 被认为是一种有前途的治疗靶点，可以降低心血管疾病的风险。近年来，重组高密度脂蛋白（rHDL）和载脂蛋白模拟肽的出现具有广阔的应用前景。在这里，我们讨论了 rHDL 的多效治疗作用，包括对动脉粥样硬化、血管生成、血小板、血管和阿尔茨海默病的影响。另一方面，rHDL 不仅作为 HDL 的主要蛋白质成分发挥关键作用，还被用作抗动脉粥样硬化、抗肿瘤、心血管诊断和其他治疗领域的纳米载体。合成载脂蛋白模拟肽，如 apoA-I 和 apoE 模拟肽，已经经过临床评估，我们还回顾了临床试验的进展，并对 rHDL 和模拟肽的治疗前景进行了展望。
